Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naive Advanced Prostate Cancer


Tuesday, 18 Mar 2014 07:00am EDT 

Astellas Pharma Inc and Medivation Inc:Submission of supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) seeking approval of XTANDI (enzalutamide) capsules.For treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy.XTANDI is approved for treatment of patients with mCRPC who have previously received docetaxel chemotherapy. 

Company Quote

1556.5
-2.5 -0.16%
10:30pm EDT